25 December 2021 : Clinical Research
Association of Perioperative Myocardial Injury with 30-Day and Long-Term Mortality in Older Adult Patients Undergoing Orthopedic Surgery in China
Wenlan Hu1BCDE, Youzhou Chen1BCD, Kaiping Zhao2BCD, Jihong Wang1BCD, Mei Zheng1BCD, Ying Zhao1BCD, Hao Han1BCD, Qiong Zhao3AE, Xingshan Zhao1AE*DOI: 10.12659/MSM.932036
Med Sci Monit 2021; 27:e932036
STROBE Statement – checklist of items that should be included in reports of observational studies.
| Item No | Recommendation | |
|---|---|---|
| √ | 1 | () Indicate the study’s design with a commonly used term in the title or the abstract |
| () Provide in the abstract an informative and balanced summary of what was done and what was found | ||
| Background √ | 2 | Explain the scientific background and rationale for the investigation being reported |
| Objectives √ | 3 | State specific objectives, including any prespecified hypotheses |
| Study design √ | 4 | Present key elements of study design early in the paper |
| Setting √ | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| Participants √ | 6 | () – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls – Give the eligibility criteria, and the sources and methods of selection of participants |
| () – For matched studies, give matching criteria and number of exposed and unexposed – For matched studies, give matching criteria and the number of controls per case | ||
| Variables √ | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/measurement √ | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias √ | 9 | Describe any efforts to address potential sources of bias |
| Study size √ | 10 | Explain how the study size was arrived at |
| Quantitative variables √ | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods √ | 12 | () Describe all statistical methods, including those used to control for confounding |
| () Describe any methods used to examine subgroups and interactions | ||
| () Explain how missing data were addressed | ||
| () – If applicable, explain how loss to follow-up was addressed – If applicable, explain how matching of cases and controls was addressed – If applicable, describe analytical methods taking account of sampling strategy | ||
| () Describe any sensitivity analyses | ||
| ParticipantsN/A | 13* | () Report numbers of individuals at each stage of study – eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| () Give reasons for non-participation at each stage | ||
| () Consider use of a flow diagram | ||
| Descriptive data √ | 14* | () Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
| () Indicate number of participants with missing data for each variable of interest | ||
| () – Summarise follow-up time (eg, average and total amount) | ||
| Outcome data √ | 15* | – Report numbers of outcome events or summary measures over time |
| – Report numbers in each exposure category, or summary measures of exposure | ||
| – Report numbers of outcome events or summary measures | ||
| Main results √ | 16 | () Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| () Report category boundaries when continuous variables were categorized | ||
| () If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | ||
| Other analysesN/A | 17 | Report other analyses done – eg analyses of subgroups and interactions, and sensitivity analyses |
| Key results √ | 18 | Summarise key results with reference to study objectives |
| Limitations √ | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation √ | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| GeneralisabilityN/A | Discuss the generalisability (external validity) of the study results | |
| Other information | ||
| FundingN/A | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
| Continued on next page * Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. | ||